

# Edward V Nunes

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3379803/edward-v-nunes-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124  
papers

4,472  
citations

34  
h-index

65  
g-index

132  
ext. papers

5,351  
ext. citations

6.2  
avg, IF

5.52  
L-index

#	Paper	IF	Citations
124	Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 291, 1887-96	27.4	397
123	Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. <i>Lancet, The</i> , <b>2011</b> , 377, 1506-13	40	371
122	Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , <b>2018</b> , 391, 309-318	40	348
121	Cognitive deficits predict low treatment retention in cocaine dependent patients. <i>Drug and Alcohol Dependence</i> , <b>2006</b> , 81, 313-22	4.9	314
120	Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1232-42	59.2	207
119	The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): procedural validity of substance use disorders modules through clinical re-appraisal in a general population sample. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 148, 40-6	4.9	152
118	Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. <i>American Journal of Psychiatry</i> , <b>2014</b> , 171, 683-90	11.9	144
117	Treatment of depression in patients with opiate dependence. <i>Biological Psychiatry</i> , <b>2004</b> , 56, 793-802	7.9	114
116	Development of a Cascade of Care for responding to the opioid epidemic. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2019</b> , 45, 1-10	3.7	111
115	Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , <b>2015</b> , 72, 593-602	14.5	104
114	Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , <b>2018</b> , 178, 764-773	11.5	96
113	Cognition, commitment language, and behavioral change among cocaine-dependent patients. <i>Psychology of Addictive Behaviors</i> , <b>2008</b> , 22, 557-62	3.4	88
112	Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. <i>Addiction</i> , <b>2013</b> , 108, 1628-37	4.6	83
111	Developing an opioid use disorder treatment cascade: A review of quality measures. <i>Journal of Substance Abuse Treatment</i> , <b>2018</b> , 91, 57-68	4.2	79
110	Procedural validity of the AUDADIS-5 depression, anxiety and post-traumatic stress disorder modules: Substance abusers and others in the general population. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 152, 246-56	4.9	77
109	Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2006</b> , 32, 503-17	3.7	73
108	Self-Report After Randomly Assigned Supervision Does not Predict Ability to Practice Motivational Interviewing. <i>Journal of Substance Abuse Treatment</i> , <b>2015</b> , 57, 96-101	4.2	65

107	Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. <i>American Journal of Psychiatry</i> , <b>2017</b> , 174, 459-467	11.9	60
106	The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 154, 38-45	4.9	57
105	Independent versus substance-induced major depressive disorder in substance-dependent patients: observational study of course during follow-up. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 1561-7	4.6	57
104	Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 159, 53-60	4.9	56
103	Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. <i>Journal of Substance Abuse Treatment</i> , <b>2018</b> , 85, 49-55	4.2	55
102	Measures of attentional bias and relational responding are associated with behavioral treatment outcome for cocaine dependence. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2012</b> , 38, 146-54	3.7	54
101	Bupropion and Naltrexone in Methamphetamine Use Disorder. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 140-153	59.2	54
100	Comorbidity of substance use with depression and other mental disorders: from Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) to DSM-V. <i>Addiction</i> , <b>2006</b> , 101 Suppl 1, 89-96	4.6	46
99	Risk/protective factors among addicted mothers' offspring: a replication study. <i>American Journal of Drug and Alcohol Abuse</i> , <b>1999</b> , 25, 661-79	3.7	46
98	Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. <i>Addiction</i> , <b>2019</b> , 114, 1416-1426	4.6	45
97	Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network. <i>Contemporary Clinical Trials</i> , <b>2012</b> , 33, 386-95	2.3	45
96	A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 923-930	11.9	42
95	Venlafaxine treatment of cocaine abusers with depressive disorders. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2000</b> , 26, 25-31	3.7	42
94	A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 129-137	11.9	42
93	NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. <i>Contemporary Clinical Trials</i> , <b>2016</b> , 50, 253-64	2.3	40
92	Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, 1075-1082	4.6	38
91	The effect of sertraline on methadone plasma levels in methadone-maintenance patients. <i>American Journal on Addictions</i> , <b>2000</b> , 9, 63-9	3.7	38
90	Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?. <i>Journal of Addiction Medicine</i> , <b>2015</b> , 9, 238-43	3.8	34

89	A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. <i>American Journal of Psychiatry</i> , <b>2020</b> , 177, 125-133	11.9	33
88	Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?. <i>Drug and Alcohol Dependence</i> , <b>2013</b> , 133, 80-5	4.9	32
87	A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. <i>Journal of Substance Abuse Treatment</i> , <b>2014</b> , 46, 546-52	4.2	30
86	Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse. <i>Annals of Internal Medicine</i> , <b>2019</b> , 170, 90-98	8	29
85	Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. <i>American Journal on Addictions</i> , <b>2018</b> , 27, 465-470 <sup>3,7</sup>	3.7	28
84	The association between naltrexone treatment and symptoms of depression in opioid-dependent patients. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2011</b> , 37, 22-6	3.7	27
83	Cost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 161, 119-26	4.9	26
82	Baseline matters: the importance of covariation for baseline severity in the analysis of clinical trials. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2011</b> , 37, 446-52	3.7	26
81	Epidemiology, Pathophysiology and Treatment of Pathological Gambling. <i>CNS Drugs</i> , <b>2000</b> , 13, 397-407	6.7	24
80	Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?. <i>Journal of Substance Abuse Treatment</i> , <b>2010</b> , 38 Suppl 1, S97-112	4.2	23
79	Utility of lead-in period in cocaine dependence pharmacotherapy trials. <i>Drug and Alcohol Dependence</i> , <b>2005</b> , 77, 7-11	4.9	23
78	Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 206, 107700	4.9	21
77	Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 147, 122-9	4.9	20
76	Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence. <i>Contemporary Clinical Trials</i> , <b>2016</b> , 51, 34-43	2.3	20
75	Pergolide mesylate for cocaine abuse: a controlled preliminary trial. <i>American Journal on Addictions</i> , <b>1999</b> , 8, 120-7	3.7	19
74	COVID-19, mental health, and opioid use disorder: Old and new public health crises intertwine. <i>Psychological Trauma: Theory, Research, Practice, and Policy</i> , <b>2020</b> , 12, S111-S112	7.8	19
73	Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 122, 108196	4.2	19
72	Acceptability of a web-based community reinforcement approach for substance use disorders with treatment-seeking American Indians/Alaska Natives. <i>Community Mental Health Journal</i> , <b>2015</b> , 51, 393-403 <sup>2,1</sup>	3.1	18

71	The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 217, 108325	4.9	18
70	Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. <i>World Psychiatry</i> , <b>2021</b> , 20, 397-404	14.4	18
69	Evaluation and treatment of mood and anxiety disorders in opioid-dependent patients. <i>Journal of Psychoactive Drugs</i> , <b>1994</b> , 26, 147-53	3.6	17
68	Cigarette Smoking During Substance Use Disorder Treatment: Secondary Outcomes from a National Drug Abuse Treatment Clinical Trials Network study. <i>Journal of Substance Abuse Treatment</i> , <b>2015</b> , 53, 39-46	4.2	16
67	Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?. <i>Journal of Substance Abuse Treatment</i> , <b>2018</b> , 85, 61-65	4.2	16
66	Web-based treatment for substance use disorders: differential effects by primary substance. <i>Addictive Behaviors</i> , <b>2015</b> , 45, 191-4	4.2	15
65	Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders. <i>American Journal on Addictions</i> , <b>2017</b> , 26, 319-325	3.7	14
64	How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis. <i>Drug and Alcohol Dependence</i> , <b>2018</b> , 188, 135-140	4.9	14
63	The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , <b>2020</b> , 112S, 4-11	4.2	13
62	Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?. <i>Drug and Alcohol Dependence</i> , <b>2014</b> , 144, 42-6	4.9	12
61	Multimodal predictive modeling of individual treatment outcome in cocaine dependence with combined neuroimaging and behavioral predictors. <i>Drug and Alcohol Dependence</i> , <b>2014</b> , 143, 29-35	4.9	10
60	Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. <i>Addictive Behaviors</i> , <b>2017</b> , 65, 74-80	4.2	10
59	Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. <i>Addiction</i> , <b>2020</b> , 115, 239-246	4.6	10
58	Young Adults Have Worse Outcomes Than Older Adults: Secondary Analysis of a Medication Trial for Opioid Use Disorder. <i>Journal of Adolescent Health</i> , <b>2020</b> , 67, 778-785	5.8	9
57	Gabapentin: a new addition to the armamentarium for alcohol dependence?. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 78-9	11.5	8
56	Dissociative identity disorder and substance abuse: the forgotten relationship. <i>Journal of Psychoactive Drugs</i> , <b>1999</b> , 31, 71-83	3.6	8
55	Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. <i>American Journal of Managed Care</i> , <b>2018</b> , 24, 526-531	2.1	8
54	New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders. <i>Current Psychiatry Reports</i> , <b>2016</b> , 18, 64	9.1	8

53	Factors Influencing Buprenorphine Prescribing among Physicians in New York State. <i>Journal of Addiction</i> , <b>2019</b> , 2019, 7832752	2.2	8
52	The "Women and Trauma" study and its national impact on advancing trauma specific approaches in community substance use treatment and research. <i>Journal of Substance Abuse Treatment</i> , <b>2020</b> , 112S, 12-17	4.2	7
51	Rationale for Using Exercise in the Treatment of Stimulant Use Disorders <b>2012</b> , 6,		7
50	Addiction Psychiatry and Addiction Medicine: The Evolution of Addiction Physician Specialists. <i>American Journal on Addictions</i> , <b>2020</b> , 29, 390-400	3.7	7
49	Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual. <i>Journal of Substance Abuse Treatment</i> , <b>2018</b> , 85, 66-69	4.2	6
48	Treatment Trajectories During and After a Medication Trial for Opioid Use Disorder: Moving from Research as Usual to Treatment as Usual. <i>Journal of Addiction Medicine</i> , <b>2020</b> , 14, 331-336	3.8	6
47	Medical Student Attitudes Toward Substance Use Disorders Before and After a Skills-Based Screening, Brief Intervention, and Referral to Treatment (SBIRT) Curriculum. <i>Advances in Medical Education and Practice</i> , <b>2020</b> , 11, 455-461	1.5	6
46	Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. <i>Drug and Alcohol Dependence</i> , <b>2019</b> , 194, 482-486	4.9	6
45	Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 660-671	11.9	6
44	Anxiety and Depressed Mood Decline Following Smoking Abstinence in Adult Smokers with Attention Deficit Hyperactivity Disorder. <i>Journal of Substance Abuse Treatment</i> , <b>2015</b> , 59, 104-8	4.2	5
43	Derived relations moderate the association between changes in the strength of commitment language and cocaine treatment response. <i>Experimental and Clinical Psychopharmacology</i> , <b>2016</b> , 24, 77-89 <sup>2</sup>	3.2	5
42	Toward National Estimates of Effectiveness of Treatment for Substance Use. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, e64-e70	4.6	5
41	Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report. <i>Substance Abuse</i> , <b>2021</b> , 42, 245-254	3.8	5
40	Workshop on the Development and Evaluation of Digital Therapeutics for Health Behavior Change: Science, Methods, and Projects. <i>JMIR Mental Health</i> , <b>2020</b> , 7, e16751	6	4
39	Quetiapine treatment for cannabis use disorder. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 218, 108366	4.9	4
38	Sociodemographic and Substance Use Disorder Determinants of HIV Sexual Risk Behavior in Men and Women in Outpatient Drug Treatment in the NIDA National Drug Abuse Treatment Clinical Trials Network. <i>Substance Use and Misuse</i> , <b>2017</b> , 52, 858-865	2.2	3
37	Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults. <i>Addictive Behaviors</i> , <b>2020</b> , 110, 106514	4.2	3
36	Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2018</b> , 44, 653-659	3.7	3

35	The design and analysis of multisite effectiveness trials: a decade of progress in the National Drug Abuse Clinical Trials Network. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2011</b> , 37, 269-72	3.7	3
34	Bromocriptine Treatment for Cocaine Addiction. <i>American Journal on Addictions</i> , <b>1993</b> , 2, 169-172	3.7	3
33	Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 215, 108221	4.9	3
32	Effects of levodopa-carbidopa-entacapone and smoked cocaine on facial affect recognition in cocaine smokers. <i>Journal of Psychopharmacology</i> , <b>2016</b> , 30, 370-7	4.6	3
31	Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 128, 108277	4.2	3
30	Exploring gender differences among treatment-seekers who use opioids versus alcohol and other drugs. <i>Women and Health</i> , <b>2020</b> , 60, 821-838	1.7	2
29	Differential Posttreatment Outcomes of Methylphenidate for Smoking Cessation for Individuals With ADHD. <i>American Journal on Addictions</i> , <b>2019</b> , 28, 497-502	3.7	2
28	Commentary on Zhou et al. (2015): Treating psychiatric comorbidity in adolescents--an important problem. <i>Addiction</i> , <b>2015</b> , 110, 49-50	4.6	2
27	COVID-19 related substance use services policy changes: Policymaker perspectives on policy development & implementation. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 108550	4.2	2
26	Workshop on Implementation Science and Digital Therapeutics for Behavioral Health. <i>JMIR Mental Health</i> , <b>2021</b> , 8, e17662	6	2
25	Medication Treatments for Opioid Use Disorder: What Is the Impact on Mood and Mood Disorders?. <i>Current Addiction Reports</i> , <b>2018</b> , 5, 303-311	3.9	2
24	Physical health problems in depressed and nondepressed children and adolescents of parents with opiate dependence <b>1999</b> , 9, 61-69		1
23	Group Psychotherapy for Treatment Refractory Methadone Maintenance Patients. <i>Journal of Maintenance in the Addictions</i> , <b>1997</b> , 1, 103-113		1
22	Commentary on Stein et al. (2020): Whither detoxification in the face of the opioid epidemic?. <i>Addiction</i> , <b>2020</b> , 115, 95-96	4.6	1
21	Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2020</b> , 46, 761-768	3.7	1
20	Psychological Symptoms and Outcomes in Adults Receiving Community-based Treatment for Substance Use Disorders. <i>Substance Use and Misuse</i> , <b>2021</b> , 56, 1258-1265	2.2	1
19	Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 124, 108292	4.2	1
18	Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis. <i>Addiction</i> , <b>2021</b> , 116, 3444-3453	4.6	1

17	Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial. <i>American Journal on Addictions</i> , <b>2021</b> , 30, 433-444	3.7	1
16	Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables. <i>Addiction</i> , <b>2021</b> , 116, 2094-2103	4.6	1
15	Optimizing opioid use disorder treatment with naltrexone or buprenorphine. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 228, 109031	4.9	1
14	Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 131, 108447	4.2	1
13	Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.. <i>Drug and Alcohol Dependence</i> , <b>2022</b> , 233, 109343	4.9	0
12	Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes. <i>Journal of Substance Abuse Treatment</i> , <b>2022</b> , 132, 108585	4.2	0
11	Patient- and Provider-Reported Experiences of a Mobile Novel Digital Therapeutic in People With Opioid Use Disorder (reSET-O): Feasibility and Acceptability Study.. <i>JMIR Formative Research</i> , <b>2022</b> , 6, e33073	2.5	0
10	Safety and efficacy of a digital therapeutic for substance use disorder: Secondary analysis of data from a NIDA clinical trials network study.. <i>Substance Abuse</i> , <b>2022</b> , 43, 937-942	3.8	0
9	Understanding site variability in a multisite clinical trial of a technology-delivered psychosocial intervention for substance use disorders. <i>Journal of Substance Abuse Treatment</i> , <b>2019</b> , 105, 64-70	4.2	
8	Responding to the Opioid Crisis: Lessons From a Review of Casualties. <i>Psychiatric Services</i> , <b>2019</b> , 70, 89	3.3	
7	Buprenorphine in the real world: coming to terms with misuse and diversion. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2018</b> , 44, 576-577	3.7	
6	Treatment of Comorbid Affective and Substance Use Disorders: Therapeutic Potential of Anticonvulsants. <i>American Journal on Addictions</i> , <b>1998</b> , 7, 210-220	3.7	
5	Lithium Treatment of Aggressive Behavior in Depressed, Drug-Dependent Patients. <i>American Journal on Addictions</i> , <b>1996</b> , 5, 87-90	3.7	
4	Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.. <i>Addiction Science &amp; Clinical Practice</i> , <b>2022</b> , 17, 6	4.1	
3	Support for COVID-19-Related Substance Use Services Policy Changes: a New York State-Wide Survey.. <i>Journal of Behavioral Health Services and Research</i> , <b>2022</b> , 1	1.7	
2	Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. <i>Addiction</i> , <b>2020</b> , 115, 2188-2190	4.6	
1	Clinical and translational research: introduction to the special issue. <i>Experimental and Clinical Psychopharmacology</i> , <b>2002</b> , 10, 155-8	3.2	